New York, January 5, 2026, 21:51 EST — Market closed
- Pfizer said CEO Albert Bourla will speak at the 44th Annual J.P. Morgan Healthcare Conference on Jan. 12, with a public webcast.
- Pfizer shares ended Monday down 0.04% at $25.17, near the middle of their $20.92-$27.69 52-week range.
- Next catalysts include Pfizer’s Feb. 3 earnings update and key U.S. data releases on Jan. 7 (ISM services PMI) and Jan. 9 (jobs report).
Pfizer said it will webcast a discussion with Chief Executive Albert Bourla at the J.P. Morgan Healthcare Conference next week, putting the drugmaker’s 2026 reset back in focus. Pfizer shares finished Monday little changed, down 0.04% at $25.17.
The San Francisco gathering is a major kickoff for healthcare investing, and it comes as Pfizer tries to convince markets it can replace fading pandemic-era revenue. The company’s initial 2026 outlook, issued in December, came in below analysts’ estimates.
That timing matters because Pfizer is navigating lower sales of its COVID-19 vaccine and treatment and approaching patent expirations on key drugs, pressures the company has said will weigh on the next few years. Investors are looking for a clearer path to sustained growth and steadier margins.
In a statement on Monday, Pfizer said Bourla will speak on Jan. 12 at 9:45 a.m. Pacific time and that a webcast will be available through its investor site. J.P. Morgan’s conference is scheduled for Jan. 12–15.
Pfizer stock has traded between $20.92 and $27.69 over the past 52 weeks, and it hit an intraday low of $24.95 on Monday before finishing near $25. The broader large-cap drugmaker group was mixed, with Merck up 0.9% and Johnson & Johnson down 1.5% on the day.
Pfizer in December projected 2026 adjusted earnings of $2.80 to $3.00 per share — “adjusted” meaning results that exclude certain items such as some acquisition-related costs — on revenue of $59.5 billion to $62.5 billion. At about $25 a share, that implies a forward price-to-earnings ratio of roughly 8 to 9.
“This stock is unlikely to break out of its current mid-20s price range until investors are convinced of a growth trajectory,” Bernstein analyst Courtney Breen said in a Dec. 16 note. Pfizer has said it does not expect to return to revenue growth until 2029.
The next scheduled company update is Feb. 3, when Pfizer plans to publish its fourth-quarter and full-year 2025 performance report and host a conference call with analysts at 10 a.m. EST, the company said. Investors will scrutinize demand trends for products including Comirnaty and Paxlovid against management’s forecasts.
Pfizer has also declared a first-quarter 2026 dividend of $0.43 a share, payable March 6 to shareholders of record on Jan. 23, it said. At Monday’s close, that equates to an annual yield of about 6.8%.
Macro data could set the tone before Bourla takes the stage. The Institute for Supply Management is due to release its services PMI — a survey-based gauge where readings above 50 indicate expansion — on Jan. 7, followed by the U.S. jobs report for December on Jan. 9, according to ISM and the Labor Department.
But investors face the risk that conference remarks bring limited new numbers, while pricing concessions, patent expiries and higher R&D spending keep earnings under pressure in 2026. The next immediate test is Bourla’s Jan. 12 webcast at the J.P. Morgan Healthcare Conference, with Pfizer’s Feb. 3 earnings update close behind.
